References
- Hofmann, Si. (1992) "Retinoids-"differentiation agents" for cancer treatment and prevention", Am. J. Med. Sci. 304, 202-213. Simoni, D. and Tolomeo, M. (2001) "Retinoids, apoptosis and cancer", Curr Phann. Des. 7, 1823–1837.
- Reynolds, C.P. and Lemons, R.S. (2001) "Retinoid therapy of childhood cancer", Hematol. Oncol. Clin. N. Am. 15, 867–910.
- Ozpolat, B. and Lopez-Berestein, G. (2002) "Liposomal-all-trans-retinoic acid in treatment of acute promyelocytic leukemia", Leuk. Lymphoma 43, 933–941.
- Hozumi, M. (1998) "Differentiation therapy of leukemia: achieve-ments, limitations and future prospects", Int. J. Hematol. 68, 107–129.
- Slack, J.L. and Gallagher, RE. (1999) "The molecular biology of acute promyelocytic leukemia", Cancer Treat. Res. 99, 75–124.
- Miyauchi, J. (1999) "All-trans retinoic acid and hematopoietic growth factors regulating the growth and differentiation of blast progenitors in acute promyelocytic leukemia", Leuk. Lymphoma 33, 267–280.
- Bruserud, 0. and Gjertsen, B.T. (2000) "New strategies for the treatment of acute myelogenous leukemia differentiation induc-tion—present use and future possibilities", Stem Cells 18, 157–165.
- Zhang, LW., Wang, J.Y., Chen, S.J. and Chen, Z. (2000) "Mechanisms of all-trans retinoic acid-induced differentiation of acute promyelocytic leukemia cells", J. Biosci. 25, 275–284.
- Degos, L. and Wang, Z.Y. (2001) "All trans retinoic acid in acute promyelocytic leukemia", Oncogene 20, 7140–7145.
- Tallman, M.S., Nabhan, C., Feusner, J.H. and Rowe, J.M. (2002) "Acute promyelocytic leukemia: evolving therapeutic strategies", Blood 99, 759–767.
- Zelent, A., Guidez, F., Melnick, A., Waxman, S. and Licht, J.D. (2001) "Translocations of the RARalpha gene in acute promyelo-cytic leukemia", Oncogene 20, 7186–7203.
- Benoit, G., Roussel, M., Pendino, F., Segal-Bendirdjian, E. and Lanotte, M. (2001) "Orchestration of multiple arrays of signal cross-talk and combinatorial interactions for maturation and cell death: another vision of t(15;17) preleukemic blast and APL-cell maturation", Oncogene 20, 7161–7177.
- Cassinat, B. and Chomienne, C. (2001) "Biological features of primary APL blasts: their relevance to the understanding of granulopoiesis, leukemogenesis and patient management", Onco-gene 20, 7154–7160.
- Sidell, N., Taga, T., Hirano, T., Kishimoto, T. and Saxon, A. (1991) "Retinoic acid-induced growth inhibition of a human myeloma cell line via down-regulation of IL-6 receptors", J. Immunol. 146, 3809–3814.
- Ogata, A., Nishimoto, N., Shima, Y, Yoshizaki, K. and Kishimoto, T. (1994) "Inhibitory effect of all-trans retinoic acid on the growth of freshly isolated myeloma cells via interference with interleukin-6 signal transduction", Blood 84, 3040–3046.
- Joseph, B., Lefebvre, 0., Mereau-Richard, C., Danze, P.M., Belin-Plancot, M.T. and Formstecher, P. (1998) "Evidence for the involvement of both retinoic acid receptor- and retinoic X receptor-dependent signaling pathways in the induction of tissue transglutaminase and apoptosis in the human myeloma cell line RP1V1I 8226", Blood 91, 2423–2432.
- Okamura, T., Masuda, M., Arai, Y, Ishida, C., Shudou, K. and Mizoguchi, H. "All-trans retinoic acid modulates Fas antigen expression and affects cell proliferation and apoptosis in combination with anti-Fas monoclonal antibody in the human myeloma cell line", U266B1. Exp. Hematol. 26, 501–506.
- Labaume, S., Chopin, M., Pla, M. and Brouet, J.C. (1998) "Differential in vitro and in vivo effects of all-trans retinoic acid on the growth of human myeloma cells", Leuk. Lymphoma 30, 361–366.
- Taetle, R., Dos Santos, B., Akamatsu, K., Koishihara, Y. and Ohsugi, Y. (1996) "Effects of all-trans retinoic acid and antireceptor antibodies on growth and programmed cell death of human myeloma cells", Clin. Cancer Res. 2, 253-259. l3l
- Tosi, P., Pellacani, A., Visani, G., Ottaviani, E., Ronconi, S., Zamagni, E., Benni, M., Cavo, M. and Tura, S. (1999) "In vitro treatment with retinoids decreases bc1-2 protein expression and enhances dexamethasone-induced cytotoxicity and apoptosis in multiple myeloma cells", Eur. J. Haematol. 62, 143–148.
- Chen, Y.H., Lavelle, D., DeSimone, J., Uddin, S., Platanias, L.C. and Hankewych, M. (1999) "Growth inhibition of a human myeloma cell line by all-trans retinoic acid is not mediated through downregulation of interleukin-6 receptors but through upregulation of p21(WAF1)", Blood 94, 251–259.
- Swaminathan, N., Lopez-Berestein, G. and Rudikoff, S. (1999) "Assessment of all-trans retinoic acid (ATRA) efficacy as a single agent in primary lymphoid neoplasia", Med. Oncol. 16, 119–128.
- Lavelle, D., Chen, Y.H., Hankewych, M. and Desimone, J. (1999) "Inhibition of myeloma cell growth by_ all-trans retinoic acid is associated with upregulation of p2lw'"1 and dephosphoryl-ation of the retinoblastoma protein", Leuk. Lymphoma 35, 261–268.
- Honemann, D., Chatterjee, M., Savino, R., Bommert, K., Burger, R., Gramatzki, M., Dorken, B. and Bargou, R.C. (2001) "The IL-6 receptor antagonist SANT-7 overcomes bone marrow stromal cell-mediated drug resistance of multiple myeloma cells", Int. J. Cancer 93, 674–680.
- Jia, P., Chen, G., Huang, X., Cai, X., Yang, J., Wang, L., Thou, Y, Shen, Y., Thou, L., Yu, Y, Chen, S., Zhang, X. and Wang, Z., "Arsenic trioxide induces multiple myeloma cell apoptosis via disruption of mitochondrial transmembrane potentials and activa-tion of caspase-3." Chin. Med. J. 114, 19–24.
- Otsuki, T., Yata, K., Sakaguchi, H., Kurebayashi, J., Matsuo, Y. Uno, M., Fujii, T., Eda, S., Isozald, Y, Yawata, Y., Yamada, 0., Wada, H., Sugihara, T. and Ueki, A., "Interleukin 10 abolishes the growth inhibitory effects of all-trans retinoic acid on human myeloma cells." Br. J. Haematol. 116, 787–795.
- Niesvizky, R., Siegel, D.S., Busquets, X., Nichols, G., Muindi, J., Warrell, R.P., Jr and Michaeli, J. (1995) "Hypercalcaemia and increased serum interleuldn-6 levels induced by all-trans retinoic acid in patients with multiple myeloma", Br J. Haematol. 89, 217–218.
- Musto, P., Sajeva, MR., Sanpaolo, G., D'Arena, G., Scalzulli, P.R. and Carotenuto, M. (1997) "All-trans retinoic acid in combination with alpha-interferon and dexamethasone for advanced multiple myeloma", Haematologica 82, 354–356.
- Gado, K., Domjan, G., Hegyesi, H. and Falus, A. (2000) "Role of INITERLEUK1N-6 in the pathogenesis of multiple myeloma", Cell Biol. Int. 24, 195–209.
- Anderson, K.C. and Lust, J.A. (1999) "Role of cytokines in multiple myeloma", Semin. Hematol. 36(1S3), 14–20.
- Gartel, Al. and Tyner, Al. (2002) "The role of the cyclin-dependent kinase inhibitor p21 in apoptosis", Mol. Cancer Titer 1, 639–649.
- Boulaire, J., Fotedar, A. and Fotedar, R. (2000) "The functions of the cdk-cyclin kinase inhibitor p21WAF1", Pathol. Biol. (Paris) 48, 190–202.
- Colman, US., Afshari, CA. and Barrett, J.C. (2000) "Regulation of p53 stability and activity in response to genotoxic stress", Mutat. Res. 462, 179–188.
- Otsuki, T., Yata, K., Sakaguchi, H., Uno, M., Fujii, T., Wada, H., Sugihara, T. and Ueki, A. (2002) "IL-10 in myeloma cells", Leuk. Lymphoma 43, 969–974.
- Otsuki, T., Yamada, 0., Yata, K., Sakaguchi, H., Kurebayashi, J., Yawata, Y. and Ueki, A. (2000) "Expression and production of interleukin 10 in human myeloma cell lines", Br. J. Haematol. 111, 835–842.
- Rozenfeld-Grano, G., Toren, A., Amariglio, N., Brok-Simoni, F. and Rechavi, G. (2001) "Mutation analysis of the FAS and TNFR apoptotic cascade genes in hematological malignancies", Exp. Hematol. 29, 228–233.
- Kastrinakis, N.G., Gorgoulis, V.G., Foukas, PG., Dimopoulos, MA. and Kittas, C. (2001) "Molecular aspects of multiple myeloma", Ann. Oncol. 11, 1217–1228.
- Landowski, T.H., Qu, N., Buyuksal, I., Painter, J.S. and Dalton, W.S. (1997) "Mutations in the Fas antigen in patients with multiple myeloma", Blood 90, 4266–4270.
- Otsuki, T., Yata, K., Sakaguchi, H., Wada, H., Sugihara, T. and Ueki, A. (2002) "Cell biological roles of IL-10 in myeloma", J. Clin. Exp. Hematopathol. 42, 1–9.
- Otsuki, T., Hata, H., Harada, N., Matsuzald, H., Yata, K., Wada, H., Yawata, Y, Ueki, A. and Yamada, 0. (2000) "Cellular biological differences between human myeloma cell lines KMS-12-PE and KMS-12-BM established from a single patient", Int. J. Hematol. 72, 216–222.
- Otsuki, T., Yamada, 0., Kurebayashi, J., Moriya, T., Sakaguchi, H., Kunisue, H., Yata, K., Uno, M., Yawat, Y. and Ueki, A. (2000) "Estrogen receptors in human myeloma cells", Cancer Res. 60, 1434–1441.
- Tanaka, K., Otsuki, T., Sonoo, H., Yamamoto, Y, Udagawa, K., Kunisue, H., Arime, I., Yamamoto, S., Kurebayashi, J. and Shimozuma, K., "Semi-quantitative comparison of the differen-tiation markers and sodium iodide symporter messenger ribonucleic acids in papillary thyroid carcinomas using RT-PCR", Eur. J. Endocrinol. 142, 340–346.
- Uno, M., Otsuki, T., Kurebayashi, J., Sakaguchi, H., Isozaki, Y, Ueki, A., Yata, K., Fujii, T., Hiratsuka, J., Akisada, T., Harada, T. and Imajo, Y. (2001) "Anti-HER2-antibody enhances irradiation-induced growth inhibition in head and neck carcinoma", Int. J. Cancer 94, 474–479.
- Yata, K., Sadahira, Y, Otsuki, T., Sakaguchi, H., Isozald, Y., Uno, M., Kurebayashi, J., Fujii, T., Eda, S., Ueki, A., Yawata, Y, Yamada, 0. and Sugihara, T. (2001) "Cell cycle analysis and expression of cell cycle regulator genes in myeloma cells overexpressing cyclin DI", Br J. Haematol. 114, 591–599.